| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/0008-5472.CAN-07-6091 |
| P698 | PubMed publication ID | 18483262 |
| P2093 | author name string | Cloud P Paweletz | |
| Sophia Randolph | |||
| Lixia Li | |||
| Stanley R Frankel | |||
| Marshall E Kadin | |||
| Andrey Loboda | |||
| Valeria R Fantin | |||
| Victoria M Richon | |||
| John F Reilly | |||
| Jennifer A Roth | |||
| Ronald C Hendrickson | |||
| Elizabeth A Harrington | |||
| Frank Gooden | |||
| Christopher M Ware | |||
| Jacqueline W Pierce | |||
| Susan Korenchuk | |||
| Xiaoli S Hou | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3785-3794 | |
| P577 | publication date | 2008-05-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma | |
| P478 | volume | 68 |
| Q38860979 | 4-(1-Ethyl-4-anisyl-imidazol-5-yl)-N-hydroxycinnamide - A new pleiotropic HDAC inhibitor targeting cancer cell signalling and cytoskeletal organisation. |
| Q33432714 | A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors |
| Q35921565 | A genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity. |
| Q34238057 | A meta-analysis of gene expression data identifies a molecular signature characteristic for tumor-stage mycosis fungoides. |
| Q40690632 | A novel approach to detect resistance mechanisms reveals FGR as a factor mediating HDAC inhibitor SAHA resistance in B-cell lymphoma |
| Q26739689 | Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies |
| Q52888457 | Apoptosis induction by SAHA in cutaneous T-cell lymphoma cells is related to downregulation of c-FLIP and enhanced TRAIL signaling. |
| Q52590685 | Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi. |
| Q37944565 | Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management |
| Q27024076 | Cutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and management |
| Q36470196 | Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management |
| Q48034709 | Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management. |
| Q37512907 | Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications |
| Q37237464 | Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma |
| Q47133172 | Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas |
| Q34606927 | Enhanced T cell lymphoma in NOD.Stat5b transgenic mice is caused by hyperactivation of Stat5b in CD8+ thymocytes |
| Q42101746 | Epigenetic Modifications: Novel Therapeutic Approach for Thyroid Cancer |
| Q51176745 | Essential Role of DNA Methyltransferase 1-mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors. |
| Q37348159 | Essential role of insulin-like growth factor 2 in resistance to histone deacetylase inhibitors |
| Q38855013 | Genetics of Cutaneous T Cell Lymphoma: From Bench to Bedside. |
| Q35066550 | Genome-wide functional genomic and transcriptomic analyses for genes regulating sensitivity to vorinostat |
| Q38058971 | HDAC inhibitor-based therapies: can we interpret the code? |
| Q37993586 | HDAC inhibitors for the treatment of cutaneous T-cell lymphomas |
| Q37962333 | HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications |
| Q37984175 | HDAC modulation and cell death in the clinic |
| Q92253988 | High activation of STAT5A drives peripheral T-cell lymphoma and leukemia |
| Q34399444 | Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies |
| Q37797706 | Histone Modification Therapy of Cancer |
| Q34488424 | Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. |
| Q82233643 | Histone deacetylase inhibitors in cancer therapy |
| Q38813504 | Histone deacetylase inhibitors in multiple myeloma: from bench to bedside |
| Q37702571 | Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma. |
| Q35592607 | Histone deacetylase inhibitors: emerging mechanisms of resistance. |
| Q37821337 | Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect |
| Q38240733 | Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders |
| Q39079713 | Inhibition of autophagy induced by TSA sensitizes colon cancer cell to radiation |
| Q90745231 | Insights Into the Molecular and Cellular Underpinnings of Cutaneous T Cell Lymphoma |
| Q38846167 | Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma |
| Q38710509 | Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes |
| Q36850845 | MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor |
| Q36020985 | Malignant T cells express lymphotoxin α and drive endothelial activation in cutaneous T cell lymphoma |
| Q37998019 | Management of cutaneous T cell lymphoma: new and emerging targets and treatment options |
| Q92445781 | Molecular Determinants of Cancer Therapy Resistance to HDAC Inhibitor-Induced Autophagy |
| Q35001132 | Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"? |
| Q27022413 | New and emerging HDAC inhibitors for cancer treatment |
| Q53059753 | Novel TBL1XR1, EPHA7 and SLFN12 mutations in a Sezary syndrome patient discovered by whole exome sequencing. |
| Q38974433 | Overview of Histone Deacetylase Inhibitors in Haematological Malignancies |
| Q37992104 | Panobinostat for the treatment of multiple myeloma |
| Q37890212 | Phosphoproteins and the dawn of functional phenotyping |
| Q33425333 | Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics. |
| Q27027751 | Predicting response to epigenetic therapy |
| Q36626781 | Predictors of response to extracorporeal photopheresis in advanced mycosis fungoides and Sézary syndrome |
| Q37962596 | Promises and challenges of anticancer drugs that target the epigenome |
| Q92475777 | Role of HDACs in normal and malignant hematopoiesis |
| Q37226511 | Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies |
| Q39303355 | Romidepsin for cutaneous T-cell lymphoma. |
| Q38455740 | Romidepsin for the treatment of non-Hodgkin's lymphoma |
| Q35683831 | Romidepsin in the treatment of cutaneous T-cell lymphoma |
| Q47140442 | Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases |
| Q37123127 | SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model |
| Q38140881 | STAT1 and STAT3 in tumorigenesis: A matter of balance. |
| Q39665695 | STAT5 induces miR-21 expression in cutaneous T cell lymphoma. |
| Q37075919 | STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma |
| Q58712956 | Single-cell heterogeneity in Sézary syndrome |
| Q33987080 | Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation. |
| Q24644201 | Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells |
| Q46517455 | Successful Treatment of Genetically Profiled Pediatric Extranodal NK/T-Cell Lymphoma Targeting Oncogenic STAT3 Mutation |
| Q38229634 | Targeted therapies for cutaneous T-cell lymphomas |
| Q37623440 | Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways |
| Q37961738 | Targeting histone deacetylases: development of vorinostat for the treatment of cancer |
| Q38233117 | Targeting of histone deacetylases in brain tumors. |
| Q39339685 | The histone deacetylase inhibitor suberoylanilide hydroxamic acid attenuates human astrocyte neurotoxicity induced by interferon-γ |
| Q34672100 | The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells. |
| Q28487756 | The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity |
| Q33783663 | Transcriptional profiles predict disease outcome in patients with cutaneous T-cell lymphoma |
| Q39285766 | Vascular endothelial growth factor receptor-3 expression in mycosis fungoides |
| Q39253408 | Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition |
| Q33800456 | Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. |
| Q35884253 | Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides |
Search more.